RESEARCH PAPER
Willingness to pay for a hypothetical HIV/AIDS insurance in Iran
Zahra Ghadimi
3,4
1
Social Development and Health Promotion Research Center, Gonabad University of Medical Sciences, Gonabad, Iran
2
Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
3
Department of Social Welfare Management, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
4
Student Research Community, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
Submission date: 2021-12-30
Final revision date: 2022-04-01
Acceptance date: 2022-04-04
Online publication date: 2024-05-18
HIV & AIDS Review 2024;23(2):160-166
KEYWORDS
TOPICS
ABSTRACT
Introduction:
In contrast to regional trend, human immunodeficiency virus (HIV) continues to be a serious health concern in Iran. Access to antiretroviral therapy is free in the country, and can result in a heavy economic burden for public sector in the near future. The purpose of this study was to investigate the willingness to pay for hypothetical HIV/acquired immunodeficiency syndrome (AIDS) insurance in people living in Tehran.
Material and methods:
A cross-sectional survey was conducted among 400 participants, aged over 23 years in 2018. The survey was conducted using multi-stage cluster sampling, and included questions on socio-demographics, exposure to HIV risk, and willingness to pay for a hypothetical insurance scheme.
Results:
The majority of participants expressed a willingness to pay for hypothetical insurance coverage within the 3-6 million IRR range, with the largest group (20.1%) willing to pay between 1-2 million IRR ($US 66-133). Fewer than half of the participants (45.3%) were willing to pay for insurance coverage, with significant variations observed among socio-demographic subgroups. The primary reason cited by participants for declining to purchase insurance was their perception of the low risk of HIV infection. After investigating socio-demographic factors, exposure to HIV risk was associated with a 9.1% higher odds of WTP (OR = 0.913; 95% CI: 816-0.968%, p < 0.01).
Conclusions:
This analysis provided initial estimations of willingness to pay for HIV/AIDS insurance in Iran. The findings can provide evidences, which can contribute to planning for a sustainable delivery of HIV treatment.
In contrast to regional trend, human immunodeficiency virus (HIV) continues to be a serious health concern in Iran. Access to antiretroviral therapy is free in the country, and can result in a heavy economic burden for public sector in the near future. The purpose of this study was to investigate the willingness to pay for hypothetical HIV/acquired immunodeficiency syndrome (AIDS) insurance in people living in Tehran.
Material and methods:
A cross-sectional survey was conducted among 400 participants, aged over 23 years in 2018. The survey was conducted using multi-stage cluster sampling, and included questions on socio-demographics, exposure to HIV risk, and willingness to pay for a hypothetical insurance scheme.
Results:
The majority of participants expressed a willingness to pay for hypothetical insurance coverage within the 3-6 million IRR range, with the largest group (20.1%) willing to pay between 1-2 million IRR ($US 66-133). Fewer than half of the participants (45.3%) were willing to pay for insurance coverage, with significant variations observed among socio-demographic subgroups. The primary reason cited by participants for declining to purchase insurance was their perception of the low risk of HIV infection. After investigating socio-demographic factors, exposure to HIV risk was associated with a 9.1% higher odds of WTP (OR = 0.913; 95% CI: 816-0.968%, p < 0.01).
Conclusions:
This analysis provided initial estimations of willingness to pay for HIV/AIDS insurance in Iran. The findings can provide evidences, which can contribute to planning for a sustainable delivery of HIV treatment.
REFERENCES (38)
2.
Armstrong-Mensah E, Ramsey-White K, Pavão CA, McCool S, Bohannon K. HIV/AIDS prevention: reducing social stigma to facilitate prevention in the developing world. Madridge J AIDS 2017; 2: 12-16.
3.
UNAIDS. Islamic Republic of Iran AIDS Progress Report On Monitoring of the United Nations General Assembly Special Session on HIV and AIDS. National AIDS Committee Secretariat, Ministry of Health and Medical Education; 2015.
4.
Khalili M, Mirzazadeh A, Chegeni M, Abedi L, Rajaei L, Ardalan G, et al. Prevalence of high-risk sexual behavior among Iranian young people: a systematic review and meta-analysis. Children and Youth Services Review 2020; 119: 105526. DOI: https://doi.org/10.1016/j.chil....
5.
WHO-EMRO. HIV in the WHO Eastern Mediterranean Region. 2021. Available at: https://www.emro.who.int/asd/a....
6.
Ghiasvand H, Shamseddin J, Naghdi S, Biglarian A. Economic burden of HIV/AIDS infection in Iran: a modelling approach. Iran J Public Health 2023; 52: 399-406.
7.
Global Burden of Disease Study [Internet]. 2021. Available at: https://www.healthdata.org/res....
8.
Joulaei H, Lankarani KB, Kazerooni PA, Marzban M. Number of HIV-infected cases in Iran: true or just an iceberg. Indian J Sex Transm Dis AIDS 2017; 38: 157-162.
9.
Aryankhesal A, Etemadi M, Mohseni M, Azami-Aghdash S, Nakhaei M. Catastrophic health expenditure in Iran: a review article. Iranian J Public Health 2018; 47: 166-177.
10.
Arani AA, Atashbar T, Antoun J, Bossert T. Iran’s health reform plan: measuring changes in equity indices. Iranian J Public Health 2018; 47: 390-396.
11.
Biener C, Eling M, Lehmann M. Balancing the desire for privacy against the desire to hedge risk. J Econ Behav Organ 2020; 180: 608-620.
12.
He AJ, Qian J, Chan WS, Chou KL. Preferences for private long-term care insurance products in a super-ageing society: a discrete choice experiment in Hong Kong. Soc Sci Med 2021; 270: 113632. DOI: https://doi.org/10.1016/j.socs....
13.
Settumba SN, Shanahan M, Botha W, Ramli MZ, Chambers GM. Reliability and validity of the contingent valuation method for estimating willingness to pay: a case of in vitro fertilisation. Appl Health Econ Health Policy 2019; 17: 103-110.
14.
Kamara J, Jofre-Bonet M, Mesnard A. A discrete choice experiment to elicit the willingness to pay for health insurance by the informal sector workers in Sierra Leone. Int J Health Econ Policy 2018; 3: 1. DOI:10.11648/j.hep.20180301.11.
15.
Tidwell JB, Terris-Prestholt F, Quaife M, Aunger R. Understanding demand for higher quality sanitation in peri-urban Lusaka, Zambia through stated and revealed preference analysis. Soc Sci Med 2019; 232: 139-147.
16.
Christell H, Gullberg J, Nilsson K, Olofsson SH, Lindh C, Davidson T. Willingness to pay for osteoporosis risk assessment in primary dental care. Health Econ Rev 2019; 9: 14. DOI: 10.1186/s13561-019-0232-z.
17.
Lin PJ, Cangelosi MJ, Lee DW, Neumann PJ. Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health 2013; 16: 797-805.
18.
Ryen L, Svensson M. The willingness to pay for a quality adjusted life year: a review of the empirical literature. Health Econ 2015; 24: 1289-1301.
19.
Jomehpour M. Assessing the livability of the new and old parts of Tehran, municipality districts 22 and 10 of Tehran. OIDA International Journal of Sustainable Development 2015; 8: 87-96.
20.
van der Pol M, Shiell A, Au F, Johnston D, Tough S. Convergent validity between a discrete choice experiment and a direct, open-ended method: comparison of preferred attribute levels and willingness to pay estimates. Soc Sci Med 2008; 67: 2043-2050.
21.
Nosratnejad S, Rashidian A, Dror DM. Systematic review of willingness to pay for health insurance in low and middle income countries. PLoS One 2016; 11: e0157470. DOI: 10.1371/journal.pone.0157470.
22.
Bala MV, Mauskopf JA, Wood LL. Willingness to pay as a measure of health benefits. Pharmacoeconomics 1999; 15: 9-18.
23.
Cameron MP, Newman PA, Roungprakhon S, Scarpa R. The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine 2013; 31: 3712-3717.
24.
Forsythe S, Arthur G, Ngatia G, Mutemi R, Odhiambo J, Gilks C. Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy and Planning 2002; 17: 187-195.
25.
Mbachu C, Okoli C, Onwujekwe O, Enabulele F. Willingness to pay for antiretroviral drugs among HIV and AIDS clients in south‐east Nigeria. Health Expect 2018; 21: 270-278.
26.
Khademi N, Saeidi S, Zangeneh A, Saeidi F, Choobtashani M. The relationship between life satisfaction and quality of life among people living with HIV/AIDS in Kermanshah‐West of Iran. Health Soc Care Commun 2020; 28: 2218-2224.
27.
Bahador M, Babashahy S, Hakimzadeh SM. Costs of HIV/AIDS: a case study in Iran. Sci Res Essays 2012; 7: 693-697.
28.
Mohaqeqi Kamal SH, Basakha M, Sajjadi H. The prevalence and risk factors of limited health literacy in Iran: a systematic review and meta-regression analysis. J Adv Med Biomed Res 2018; 26: 1-8.
29.
National Health Accounts [Internet]. Statistical Center of Iran 2021. Available at: https://amar.org.ir/ gozideamari/articleType/CategoryView/categoryId/49/%D8%AD%D8%B3%D8%A7%D8%A8-%D9%87%D8%A7%DB%8C-%D8%A7%D9%82%D9%85%D8%A7%D8%B1%DB%8C (Accessed: 30.04.2022).
30.
Alo CN, Okedo-Alex IN, Akamike IC. Determinants of willingness to participate in health insurance amongst people living with HIV in a tertiary hospital in South-East Nigeria. Niger Postgrad Med J 2020; 27: 196-201.
31.
Shigeoka H. The effect of patient cost sharing on utilization, health, and risk protection. Am Econ Rev 2014; 104: 2152-2184.
32.
Barnes K, Mukherji A, Mullen P, Sood N. Financial risk protection from social health insurance. J Health Econ 2017; 55: 14-29.
33.
Finkelstein A, Hendren N, Luttmer EF. The value of medicaid: interpreting results from the oregon health insurance experiment. J Political Econ 2019; 127: 2836-2874.
34.
Jaspersen JG, Ragin MA, Sydnor JR. Predicting insurance demand from risk attitudes. Journal of Risk and Insurance 2022; 89: 63-96.
35.
Hillebrecht M, Klonner S, Sauerborn R, Sié A, Souares A. The demand for health insurance in a poor economy: evidence from Burkina Faso. Economic Development and Cultural Change 2021; 69: 1273-1300.
36.
Baillon A, Kraft A, O’Donnell O, van Wilgenburg K. A behavioral decomposition of willingness to pay for health insurance. Journal of Risk and Uncertainty 2022; 64: 43-87.
37.
Sukartini T, Nursalam N, Arifin H. The determinants of willingness to care for people living with HIV‐AIDS: A cross‐sectional study in Indonesia. Health Soc Care Commun 2021; 29: 809-817.
38.
Winn S. The role of the primary health care team in the care of people with HIV and AIDS. Health Soc Care Commun 1997; 5: 408-417.
Share
RELATED ARTICLE
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
